4 completed, 1 not yet recruiting, 1 withdrawn. 6 Phase 1, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 6 | Completed 4, Not yet recruiting 1, Withdrawn 1 |
| Phase 2 | 2 | Completed 1, Withdrawn 1 |
Follow CP protocol: new trials by email Literature Review of CP protocol trials Research Report on CP protocol
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| HSK41959 With Standard Therapy in Solid Tumors With MTAP Deletion HSK41959, Sintilimab, Pemetrexed + Cisplatin /Carboplatin - Non-Small Cell Lung Cancer, Pancreatic Ductal Adenocarcinoma (mPDAC) | Phase 1 | Not yet recruiting | Haisco Pharmaceutical Group Co., Ltd. | 258 | 2026-07-01 | 2026-07-14 |
| Uterine Serous Carcinoma and Adjuvant Combined Intraperitoneal Chemotherapy and Radiation Paclitaxel/Carboplatin, Pelvic radiation therapy - Uterine Carcinoma | Phase 1 / Phase 2 | Withdrawn | Northwell Health | 2020-05-20 | 2023-03-17 | |
| Study of Niraparib, TSR-022, Bevacizumab, and Platinum-Based Doublet Chemotherapy in Combination With TSR-042 Niraparib, TSR-042, Carboplatin-Paclitaxel - Neoplasms, Metastatic Cancer | Phase 1 | Completed | Tesaro, Inc. | 60 | 2017-10-12 | 2025-11-25 |
| Durvalumab and Tremelimumab in Combination With First-Line Chemotherapy in Advanced Solid Tumors paclitaxel + carboplatin, carboplatin + etoposide, gemcitabine + carboplatin - Small Cell Lung Carcinoma, Carcinoma, Squamous Cell of Head and Neck | Phase 1 | Completed | AstraZeneca | 32 | 2016-04-28 | 2020-08-20 |
| Comparison of Weekly Versus Every Three Weeks of Carboplatin Plus Paclitaxel in Patients With Advanced Epithelial Ovarian Cancer Carboplatin/paclitaxel - Advanced Epithelial Ovarian Cancer | Phase 1 / Phase 2 | Completed | Cairo University | 49 | 2015-01-01 | 2023-07-27 |
| Study to Assess the Safety and Tolerability of a PARP Inhibitor in Combination With Carboplatin and/or Paclitaxel KU-0059436 (AZD2281)(PARP inhibitor), Carboplatin, Paclitaxel - Triple Negative Metastatic Breast Cancer, Advanced Ovarian Cancer | Phase 1 | Completed | AstraZeneca | 189 | 2007-06-22 | 2025-04-11 |
Carcinoma, Non-Small-Cell Lung (2) · Neoplasm Metastasis (2) · Anemia (1) · Carcinoma, Pancreatic Ductal (1) · Esophageal Squamous Cell Carcinoma (1) · Fallopian Tube Neoplasms (1) · Neoplasms (1) · Neutropenia (1) · Ovarian Neoplasms (1) · Peritoneal Neoplasms (1) · Small Cell Lung Carcinoma (1) · Squamous Cell Carcinoma of Head and Neck (1) · Stomach Neoplasms (1) · Thrombocytopenia (1) · Triple Negative Breast Neoplasms (1)
AstraZeneca (2) · Cairo University (1) · Haisco Pharmaceutical Group Co., Ltd. (1) · Northwell Health (1) · Tesaro, Inc. (1)
United States (2) · Belgium (1) · China (1) · Egypt (1) · Japan (1) · Netherlands (1) · South Korea (1) · United Kingdom (1)
Dr Johann de Bono, MD (1) · Jane Robertson, BSc, MBCHB, MD (1) · Karin Shih, MD (1) · Prof Jan HM Schellens (1)
PMID 11020574, PMID 15169803, PMID 15459211, PMID 15913742, PMID 16330675, PMID 1989916, PMID 21436701, PMID 21508697, PMID 2211199, PMID 2211200, PMID 22248721, PMID 2258085, PMID 2323606, PMID 2380095, PMID 2412690, PMID 2745205, PMID 3053592, PMID 31637669, PMID 31667659, PMID 37489066, PMID 4055452, PMID 6999399, PMID 7102898, PMID 7617840, PMID 7729725, PMID 8088602, PMID 8381710, PMID 8490920, PMID 8522260, PMID 8751561, PMID 8859187